EP1578365A4 - Molekulare interaktionen in neuronen - Google Patents

Molekulare interaktionen in neuronen

Info

Publication number
EP1578365A4
EP1578365A4 EP03768964A EP03768964A EP1578365A4 EP 1578365 A4 EP1578365 A4 EP 1578365A4 EP 03768964 A EP03768964 A EP 03768964A EP 03768964 A EP03768964 A EP 03768964A EP 1578365 A4 EP1578365 A4 EP 1578365A4
Authority
EP
European Patent Office
Prior art keywords
neurons
molecular interactions
interactions
molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03768964A
Other languages
English (en)
French (fr)
Other versions
EP1578365A2 (de
Inventor
Peter S Lu
Jonathan David Garman
Michael P Belmares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbor Vita Corp
Original Assignee
Arbor Vita Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Vita Corp filed Critical Arbor Vita Corp
Publication of EP1578365A2 publication Critical patent/EP1578365A2/de
Publication of EP1578365A4 publication Critical patent/EP1578365A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03768964A 2002-11-14 2003-11-14 Molekulare interaktionen in neuronen Withdrawn EP1578365A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42621302P 2002-11-14 2002-11-14
US42621202P 2002-11-14 2002-11-14
US426213P 2002-11-14
US426212P 2002-11-14
PCT/US2003/036698 WO2004045535A2 (en) 2002-11-14 2003-11-14 Molecular interactions in neurons

Publications (2)

Publication Number Publication Date
EP1578365A2 EP1578365A2 (de) 2005-09-28
EP1578365A4 true EP1578365A4 (de) 2009-09-23

Family

ID=32329101

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03768964A Withdrawn EP1578365A4 (de) 2002-11-14 2003-11-14 Molekulare interaktionen in neuronen

Country Status (3)

Country Link
EP (1) EP1578365A4 (de)
CA (1) CA2505479A1 (de)
WO (1) WO2004045535A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6942981B1 (en) 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005061548A1 (en) * 2003-12-23 2005-07-07 Nono Inc. Polypeptides for modulating binding of trp channel proteins and trp-associated proteins.
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2007002395A1 (en) 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
US8685925B2 (en) 2006-07-11 2014-04-01 Nono Inc. Method and compositions for treating stroke with fever
EP1884521A1 (de) * 2006-07-31 2008-02-06 Xigen S.A. Fusionspeptide zur Hemmung der Wechselwirkung zwischen den neuronalen NDMA Rezeptor und damit NMDAR interagierende Proteine
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
HUE053131T2 (hu) * 2009-06-10 2021-06-28 Nono Inc Kezelési rendszer neurológiai betegség kezelésére
HUE046640T2 (hu) 2009-06-10 2020-03-30 Nono Inc TAT-internalizáló peptidhez kapcsolt hatóanyag együttes beadása egy hízósejt degranuláció-inhibitorral
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
EP2581384A1 (de) * 2011-10-11 2013-04-17 Institut Pasteur Zur Behandlung maligner Neoplasmen des menschlichen Nervensystems nützliche Produkte
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CN106554386A (zh) * 2015-09-25 2017-04-05 广州恒上医药技术有限公司 人乳头瘤病毒的表位肽及其应用
CN111712252A (zh) 2017-12-13 2020-09-25 纽约州立大学研究基金会 用于治疗疼痛和提高疼痛敏感性的肽和其它药剂
EP3762028A4 (de) * 2018-03-08 2021-12-15 Phanes Therapeutics, Inc. Anti-tip-1-antikörper und verwendungen davon
CN114807142B (zh) * 2022-05-26 2024-03-29 源生生物科技(青岛)有限责任公司 一种环状RNA-circ-Magi1及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273622A1 (en) * 1999-06-02 2000-12-02 Michael Tymianski Inhibition of nmda receptor signalling in reducing neuronal damage
WO2002007751A1 (en) * 2000-07-25 2002-01-31 Axcell Biosciences Corporation Identification and isolation of novel polypeptides having pdz domains and methods of using same
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
WO2002090981A1 (fr) * 2001-05-08 2002-11-14 Japan Science And Technology Corporation Antigene antitumoral contre la contre la tumeur htlv-1 ou son epitope
WO2003014303A2 (en) * 2001-08-03 2003-02-20 Arbor Vita Corporation Molecular interactions in cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273622A1 (en) * 1999-06-02 2000-12-02 Michael Tymianski Inhibition of nmda receptor signalling in reducing neuronal damage
WO2002007751A1 (en) * 2000-07-25 2002-01-31 Axcell Biosciences Corporation Identification and isolation of novel polypeptides having pdz domains and methods of using same
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
WO2002090981A1 (fr) * 2001-05-08 2002-11-14 Japan Science And Technology Corporation Antigene antitumoral contre la contre la tumeur htlv-1 ou son epitope
EP1391729A1 (de) * 2001-05-08 2004-02-25 Japan Science and Technology Corporation Antitumor-antigen gegen einen htlv-1-tumor oder ein antigenepitop davon
WO2003014303A2 (en) * 2001-08-03 2003-02-20 Arbor Vita Corporation Molecular interactions in cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AARTS MICHELLE ET AL: "Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, WASHINGTON, DC, vol. 298, no. 5594, 25 October 2002 (2002-10-25), pages 846 - 850, XP002456870, ISSN: 0036-8075 *
KORNAU H-C ET AL: "Domain Interaction Between NMDA Receptor Subunits and the Postsynaptic Density Protein PSD-95", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, WASHINGTON, DC, vol. 269, no. 5231, 1 September 1995 (1995-09-01), pages 1737 - 1740, XP002196675, ISSN: 0036-8075 *
LIM I A ET AL: "Selectivity and promiscuity of the first and second PDZ domains of PSD-95 and synapse-associated protein 102", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 277, no. 24, 14 June 2002 (2002-06-14), pages 21697 - 21698, XP002991766, ISSN: 0021-9258 *
ROUSSET R ET AL: "THE C-TERMINUS OF THE HTLV-1 TAX ONCOPROTEIN MEDIATES INTERACTION WITH THE PDZ DOMAIN OF CELLULAR PROTEINS", ONCOGENE, NATURE PUBLISHING GROUP, GB BASINGSTOKE, HANTS, vol. 16, no. 5, 5 February 1998 (1998-02-05), pages 643 - 654, XP000865909, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
WO2004045535A3 (en) 2006-07-13
WO2004045535A2 (en) 2004-06-03
CA2505479A1 (en) 2004-06-03
EP1578365A2 (de) 2005-09-28

Similar Documents

Publication Publication Date Title
EP1578365A4 (de) Molekulare interaktionen in neuronen
AU2003228850A8 (en) Single trial detection in encephalography
AU2003294503A8 (en) Molecular nephrotoxicology modeling
GB2418259B (en) Improvements in touch technology
EP1443951A4 (de) Molekulare wechselwirkungen in zellen
GB2392946B (en) Improvements in control units
AU2003268003A8 (en) Diamondoid-based components in nanoscale construction
DE60333033D1 (en) Pulverförmiges thermoplastisches polymer
GB0317244D0 (en) Polymer
EP1501722A4 (de) Verbesserungen bei bugsprieten
AU2003235768A8 (en) Molecular trichogram
AU2003239679A1 (en) Improvements in greetins cards
EP1487547A4 (de) Mittel zur körperlichen wechselwirkung und seine verwandten verwendungen
GB2428804B (en) Improvements in touch technology
GB0311936D0 (en) Improvements in devices
GB2396429B (en) Elasticity in plastics processing
GB0221366D0 (en) Molecular model
GB0201593D0 (en) Ferromagnetic polymer
GB0321462D0 (en) Molecular model
AU2003900725A0 (en) Improvements in lock - cont 5
AU2003900493A0 (en) Improvements in lock - cont 4
AU2003900103A0 (en) Improvements in lock - Cont 3
GB0204072D0 (en) Music once you step in
GB0324811D0 (en) Improvements in magnetopolariscopes
AU2003900838A0 (en) Improvements in lock - Cont. 6

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050530

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/06 20060101ALI20060907BHEP

Ipc: A61K 38/04 20060101ALI20060907BHEP

Ipc: A61K 38/00 20060101ALI20060907BHEP

Ipc: A01N 37/18 20060101AFI20060907BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090821

17Q First examination report despatched

Effective date: 20091209

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110215